Related Experiment Videos
Growth, puberty and endocrine function in beta-thalassaemia major
1Department of Paediatrics, University of Hong Kong, Hong Kong.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|March 1, 1997
Summary
Growth failure in thalassemia patients can stem from delayed puberty, iron overload, or endocrine issues. Growth hormone therapy shows promise for short children, but long-term height outcomes require further study.
Area of Science:
- Pediatric Endocrinology
- Hematology
- Metabolic Disorders
Background:
- Thalassemia patients often experience growth failure due to delayed puberty, iron overload, and endocrinopathies like GH insufficiency or hypothyroidism.
- Abnormal body proportions, including truncal shortening, are common and linked to the disease, iron toxicity, or treatment side effects.
- Achieving normal adult height is challenged by the absence of a pubertal growth spurt.
Purpose of the Study:
- To investigate the causes of growth failure in adolescent thalassemia patients.
- To evaluate the effectiveness of growth hormone (GH) therapy in short, non-GH deficient thalassemia children.
- To highlight the importance of managing endocrinopathies and iron overload for improved survival and growth.
Main Methods:
- Analysis of growth patterns, hormonal profiles (IGF-I, GH reserve), and body proportions in short thalassemia patients.
- Assessment of short-term outcomes of growth hormone (GH) therapy.
- Review of endocrinopathy prevalence and management strategies, including chelation therapy and puberty induction.
Main Results:
- Short thalassemia children exhibit relative GH resistance, indicated by low serum IGF-I and normal GH reserve.
- Short-term GH therapy improves IGF-I levels and growth, but its impact on final adult height is uncertain.
- Endocrinopathies (hypogonadism, hypothyroidism, diabetes) are more prevalent in older patients with high ferritin levels.
Conclusions:
- Growth hormone (GH) resistance is a significant factor in growth failure among thalassemia patients.
- Optimizing chelation therapy to maintain serum ferritin below 2000 µg/L is crucial for survival.
- Early intervention for delayed puberty and careful management of iron overload and treatment toxicity are essential for improving growth and prognosis.